Multicentre validation of CT grey-level co-occurrence matrix features for overall survival in primary oesophageal adenocarcinoma
Robert O’Shea,Samuel J. Withey,Kasia Owczarczyk,Christopher Rookyard,James Gossage,Edmund Godfrey,Craig Jobling,Simon L. Parsons,Richard J. E. Skipworth,Vicky Goh,Rebecca C. Fitzgerald,Paul A. W. Edwards,Nicola Grehan,Barbara Nutzinger,Aisling M. Redmond,Sujath Abbas,Adam Freeman,Elizabeth C. Smyth,Maria O’Donovan,Ahmad Miremadi,Shalini Malhotra,Monika Tripathi,Calvin Cheah,Hannah Coles,Matthew Eldridge,Maria Secrier,Ginny Devonshire,Sriganesh Jammula,Jim Davies,Charles Crichton,Nick Carroll,Richard H. Hardwick,Peter Safranek,Andrew Hindmarsh,Vijayendran Sujendran,Stephen J. Hayes,Yeng Ang,Andrew Sharrocks,Shaun R. Preston,Izhar Bagwan,Vicki Save,J. Robert O’Neill,Olga Tucker,Andrew Beggs,Philippe Taniere,Sonia Puig,Gianmarco Contino,Timothy J. Underwood,Ben L. Grace,Jesper Lagergren,Andrew Davies,Fuju Chang,Ula Mahadeva,Francesca D. Ciccarelli,Grant Sanders,David Chan,Ed Cheong,Bhaskar Kumar,Loveena Sreedharan,Irshad Soomro,Philip Kaye,John Saunders,Laurence Lovat,Rehan Haidry,Michael Scott,Sharmila Sothi,George B. Hanna,Christopher J. Peters,Krishna Moorthy,Anna Grabowska,Richard Turkington,Damian McManus,Helen Coleman,Russell D. Petty,Freddie Bartlett,Tom D. L. Crosby,
DOI: https://doi.org/10.1007/s00330-024-10666-y
IF: 7.034
2024-03-25
European Radiology
Abstract:Abstract Background Personalising management of primary oesophageal adenocarcinoma requires better risk stratification. Lack of independent validation of proposed imaging biomarkers has hampered clinical translation. We aimed to prospectively validate previously identified prognostic grey-level co-occurrence matrix (GLCM) CT features for 3-year overall survival. Methods Following ethical approval, clinical and contrast-enhanced CT data were acquired from participants from five institutions. Data from three institutions were used for training and two for testing. Survival classifiers were modelled on prespecified variables (‘Clinical’ model: age, clinical T-stage, clinical N-stage; ‘ClinVol’ model: clinical features + CT tumour volume; ‘ClinRad’ model: ClinVol features + GLCM_Correlation and GLCM_Contrast). To reflect current clinical practice, baseline stage was also modelled as a univariate predictor (‘Stage’). Discrimination was assessed by area under the receiver operating curve (AUC) analysis; calibration by Brier scores; and clinical relevance by thresholding risk scores to achieve 90% sensitivity for 3-year mortality. Results A total of 162 participants were included (144 male; median 67 years [IQR 59, 72]; training, 95 participants; testing, 67 participants). Median survival was 998 days [IQR 486, 1594]. The ClinRad model yielded the greatest test discrimination (AUC, 0.68 [95% CI 0.54, 0.81]) that outperformed Stage (ΔAUC, 0.12 [95% CI 0.01, 0.23]; p = .04). The Clinical and ClinVol models yielded comparable test discrimination (AUC, 0.66 [95% CI 0.51, 0.80] vs. 0.65 [95% CI 0.50, 0.79]; p > .05). Test sensitivity of 90% was achieved by ClinRad and Stage models only. Conclusions Compared to Stage, multivariable models of prespecified clinical and radiomic variables yielded improved prediction of 3-year overall survival. Clinical relevance statement Previously identified radiomic features are prognostic but may not substantially improve risk stratification on their own. Key Points • Better risk stratification is needed in primary oesophageal cancer to personalise management. • Previously identified CT features—GLCM_Correlation and GLCM_Contrast—contain incremental prognostic information to age and clinical stage. • Compared to staging, multivariable clinicoradiomic models improve discrimination of 3-year overall survival.
radiology, nuclear medicine & medical imaging